Key Drivers
- High profitability
- Very high leverage
- Limited liquidity
AIAI Summary
Amgen has shifted from a dividend blue‑chip to a high‑execution transition play where its ~ $54.6B debt load and imminent biosimilar revenue cliff mean near‑term returns hinge on whether launches (MariTide, Imdelltra, olpasiran) can scale quickly enough to replace legacy losses and enable meaningful debt reduction—if not, treat the stock as a hold/watch until proof of rapid commercial uptake or balance‑sheet repair appears.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High profitability
- •Very high leverage
- •Limited liquidity
AMGN generates strong margins and cash flow but is highly leveraged with modest liquidity and elevated valuation, creating a balanced but risk‑sensitive investment profile.
Price Behavior
Key Price Behavior Insights:
- •Below moving average
- •Failed resistance test
- •Pullback to $347.80
Short-term downtrend: price sits below last month's 21-day average (~$371.8) after failing to hold the $375–388 resistance band and pulling back to $347.80, with a sustained move above $371–375 needed to signal reversal.
Sharp pullback from ~$388 to $347.80 since late
Sentiment & News
Key News Insights:
- •Product growth
- •Mixed coverage
- •Institutional shifts
Amgen draws investor interest on strong product-driven sales and technical strength but faces mixed analyst sentiment and active institutional rebalancing that could keep the stock volatile.
Strong sales and pipeline momentum support the share price but mixed broker views and portfolio trimming signal potential near-term volatility
Similar Companies in Healthcare
Other companies in the same sector with AI ratings